Metabolic disorders and androgen deficiency in the pathogenesis of urolithiasis
- Authors: Emirgaev Z.K.1, Tagirov R.N.1, Tagirov N.S.1, Vasiliev A.G.1
-
Affiliations:
- Saint Petersburg State Pediatric Medical University
- Issue: Vol 15, No 1 (2024)
- Pages: 65-78
- Section: Reviews
- URL: https://journals.rcsi.science/pediatr/article/view/263097
- DOI: https://doi.org/10.17816/PED15165-78
- ID: 263097
Cite item
Abstract
This review summarizes and critically analyzes current data on the pathogenesis of urolithiasis (urolithiasis, nephrolithiasis). Emphasis is placed on such issues as: mechanisms of urinary stone formation; risk factors for stone formation; the role of oxidative stress; the chemical composition of renal stones (and especially oxalates); the role of Randall’s plaques, osteopontin, uromodulin (Tamm–Horsfall protein), α-enolase; and the mechanism of stone formation in the collecting ducts. Insufficiently studied issues of microbiota influence — (a) kidney and urinary tract and (b) gastrointestinal tract are also considered. Attention is paid to new approaches to understanding the pathogenesis and treatment of urolithiasis, namely works on genetics, epigenetics, genetic engineering and proteomics. The imperfection of existing animal models of urolithiasis is shown. The issue of application of androgen replacement therapy in the treatment of patients suffering from urolithiasis is considered separately. The author considers the main theoretical result of his work to be the approval of the idea of urolithiasis as a systemic disease, in which any significant deviation of the internal environment constants violates the delicate balance that ensures the solubility of substances in primary urine and their excretion with secondary urine. The practical result is to confirm the applicability of androgen replacement therapy in the treatment of patients suffering from urolithiasis.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Zaur K. Emirgaev
Saint Petersburg State Pediatric Medical University
Email: zzemir@mail.ru
SPIN-code: 6771-7532
Postgraduate Student, Pathophysiology Department
Russian Federation, 2 Litovskaya str., Saint Petersburg, 194100Ruslan N. Tagirov
Saint Petersburg State Pediatric Medical University
Email: avas7@mail.ru
Student
Russian Federation, 2 Litovskaya str., Saint Petersburg, 194100Nair S. Tagirov
Saint Petersburg State Pediatric Medical University
Email: ruslana73nair@mail.ru
ORCID iD: 0000-0002-4362-3369
SPIN-code: 9810-1650
MD, PhD, Dr. Sci. (Medicine), Professor, Pathophysiology Department
Russian Federation, 2 Litovskaya str., Saint Petersburg, 194100Andrei G. Vasiliev
Saint Petersburg State Pediatric Medical University
Author for correspondence.
Email: avas7@mail.ru
ORCID iD: 0000-0002-8539-7128
SPIN-code: 1985-4025
Scopus Author ID: 56496365400
ResearcherId: F-8743-2017
https://www.gpmu.org/eng/university_eng/departments/Pathological_physiology/Vasiliev/
MD, PhD, Dr. Sci. (Medicine), Professor, Head of Pathophysiology Department
Russian Federation, 2 Litovskaya str., Saint Petersburg, 194100References
- Anichkova IV, Arkhipov VV, Benameño JP, et al. Clinical pediatric nephrology. Saint Petersburg: Sotis; 1997. 717 p. EDN: VRKSMB
- Apolikhin OI, Sivkov AV, Solntseva TV, Komarova VA. Analysis of urological morbidity in the Russian Federation within the period of 2005–2010. Experimental and Clinic Urology. 2012(2):64–72. EDN: PDARKJ
- Gadzhiev NK, Malkhasyan VA, Mazurenko DV, et al. Urolithiasis and metabolic syndrome. Pathophysiology of stone formation. Experimental & Clinical Urology. 2018;(1):66–75. EDN: WCZJLF
- Nazarov TH, Guliev BG, Stetsik OV, et al. Diagnostics and correction of metabolic disorders in patients with recurrent urolithiasis after endoscopic removal of stones. Andrology and Genital Surgery. 2015;16(3):22–28. EDN: ULHBXH doi: 10.17650/2070-9781-2015-16-3-22-28
- Nitkin DM. Predictors of recurrent urolithiasis in patients with age-related androgenic disorders. Medical News. 2017;(11):53–56. EDN: XGLPPA
- Smirnova NN, Kuprienko NB. Uromodulin and its role in the formation of renal components in children and adolescents. Children’s Medicine of the North-West. 2022;10(1):44–48.
- Tagirov NS, Trashkov AP, Balashov LD, Balashov NA. The role of androgenous deficiency in the development of urolitiasis in experimental ethylenglycol rat model. Pediatrician (St. Petersburg). 2015;6(3):86–90. doi: 10.17816/PED6386-90
- Tagirov NS. Pathogenetic correction of metabolic disorders and androgen deficiency in the treatment of patients with urolithiasis (clinical and experimental study) [Dissertation]. Saint Petersburg; 2019. 256 p. (In Russ.) Available from: https://vmeda.mil.ru/upload/site56/document_file/h5OPaCxTzp.pdf
- Trashkov AP, Vasiliev AG, Kovalenko AD, Tagirov NS. Metabolic therapy of nephrolithiasis in two different rat models of kidney disease. Éksperimentalnaya i Klinicheskaya Farmakologiya. 2015;78(3):17–21. EDN: TNJRKB
- Shuster PI, Glybochko PV. Condition of lithogenesis processes in kidneys secondary to androgynous therapies lithogenesis processes in kidneys at receiving androgynous therapy. Saratov Journal of Medical Scientific Research. 2009;5(4):612–615. EDN: KXWZOF
- Aggarwal KP, Narula S, Kakkar M, Tandon C. Nephrolithiasis: molecular mechanism of renal stone formation and the critical role played by modulators. Biomed Res Int. 2013;2013:292953. doi: 10.1155/2013/292953
- Akagi S, Sugiyama H, Makino H. [Infection and chronic kidney disease]. Nihon Rinsho. 2008;66(9):1794–1798. (In Japanese).
- Al KF, Daisley BA, Chanyi RM, Bjazevic J, et al. Oxalate-degrading bacillus subtilis mitigates urolithiasis in a drosophila melanogaster model. mSphere. 2020;5(5):e00498–e00420. doi: 10.1128/mSphere.00498-20
- Alelign T, Petros B. Kidney stone disease: an update on current concepts. Adv Urol. 2018;2018:3068365. doi: 10.1155/2018/3068365
- Alshehri M, Alsaeed H, Alrowili M, et al. Evaluation of risk factors for recurrent renal stone formation among Saudi Arabian patients: Comparison with first renal stone episode. Arch Ital Urol Androl. 2023;95(3):11361. doi: 10.4081/aiua.2023.11361
- Arcidiacono T, Mingione A, Macrina L, et al. Idiopathic calcium nephrolithiasis: a review of pathogenic mechanisms in the light of genetic studies. Am J Nephrol. 2014;40(6):499–506. doi: 10.1159/000369833
- Bagga HS, Chi T, Miller J, Stoller ML. New insights into the pathogenesis of renal calculi. Urol Clin North Am. 2013;40(1):1–12. doi: 10.1016/j.ucl.2012.09.006
- D’Ambrosio V, Ferraro PM, Lombardi G, et al. Unravelling the complex relationship between diet and nephrolithiasis: the role of nutrigenomics and nutrigenetics. Nutrients. 2022;14(23):4961. doi: 10.3390/nu14234961
- Chaiyarit S, Thongboonkerd V. Mitochondrial dysfunction and kidney stone disease. Front Physiol. 2020;11:566506. doi: 10.3389/fphys.2020.566506
- Changtong C, Peerapen P, Khamchun S, et al. In vitro evidence of the promoting effect of testosterone in kidney stone disease: A proteomics approach and functional validation. J Proteomics. 2016;144:11–22. doi: 10.1016/j.jprot.2016.05.028
- Chung HJ. The role of Randall plaques on kidney stone formation. Transl Androl Urol. 2014;3(3):251–254. doi: 10.3978/j.issn.2223-4683.2014.07.03
- Coe FL, Worcester EM, Evan AP. Idiopathic hypercalciuria and formation of calcium renal stones. Nat Rev Nephrol. 2016;12(9): 519–533. doi: 10.1038/nrneph.2016.101
- Daudon M, Bouzidi H, Bazin D. Composition and morphology of phosphate stones and their relation with etiology. Urological Research. 2010;38(6):459–467. doi: 10.1007/s00240-010-0320-3
- Emami E, Heidari-Soureshjani S, Oroojeni Mohammadjavad A, Sherwin CM. Obesity and the risk of developing kidney stones: a systematic review and meta-analysis. Iran J Kidney Dis. 2023;1(2):63–72.
- Ermer T, Nazzal L, Tio MC, et al. Oxalate homeostasis. Nat Rev Nephrol. 2023;19(2):123–138. doi: 10.1038/s41581-022-00643-3
- Espinosa-Ortiz EJ, Eisner BH, Lange D, Gerlach R. Current insights into the mechanisms and management of infection stones. Nat Rev Urol. 2019;16(1):35–53. doi: 10.1038/s41585-018-0120-z
- Evan A, Lingeman J, Coe FL, Worcester E. Randall’s plaque: pathogenesis and role in calcium oxalate nephrolithiasis. Kidney Int. 2006;69(8):1313–1318. doi: 10.1038/sj.ki.5000238
- Evan AP, Worcester EM, Coe FL, et al. Mechanisms of human kidney stone formation. Urolithiasis. 2015;43(S1):19–32. doi: 10.1007/s00240-014-0701-0
- Fuster DG, Morard GA, Schneider L, et al. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. Nephrol Dial Transplant. 2022;37(2):335–348. doi: 10.1093/ndt/gfaa360
- Gao H, Lin J, Xiong F, Yu Z, et al. Urinary microbial and metabolomic profiles in kidney stone disease. Front Cell Infect Microbiol. 2022;12:953392. doi: 10.3389/fcimb.2022.953392
- Gianmoena K, Gasparoni N, Jashari A, et al. Epigenomic and transcriptional profiling identifies impaired glyoxylate detoxification in NAFLD as a risk factor for hyperoxaluria. Cell Rep. 2021;36(8):109526. doi: 10.1016/j.celrep.2021.109526
- Gupta K, Gill GS, Mahajan R. Possible role of elevated serum testosterone in pathogenesis of renal stone formation. Int J Appl Basic Med Res. 2016;6(4):241–244. doi: 10.4103/2229–516X.192593
- Hamano S, Nakatsu H, Suzuki N, et al. Kidney stone disease and risk factors for coronary heart disease. Int J Urol. 2005;12(10): 859–863. doi: 10.1111/j.1442-2042.2005.01160.x
- Hsi RS, Ramaswamy K, Ho SP, Stoller ML. The origins of urinary stone disease: upstream mineral formations initiate downstream Randall’s plaque. BJU Int. 2017;119(1):177–184. doi: 10.1111/bju.13555
- Jeong JY, Oh KJ, Sohn JS, et al. Clinical course and mutational analysis of patients with cystine stone: a single-center experience. Biomedicines. 2023;11(10):2747. doi: 10.3390/biomedicines11102747
- Jung HD, Cho S, Lee JY. Update on the effect of the urinary microbiome on urolithiasis. Diagnostics (Basel). 2023;13(5):951. doi: 10.3390/diagnostics13050951
- Khan SR. Is oxidative stress, a link between nephrolithiasis and obesity, hypertension, diabetes, chronic kidney disease, metabolic syndrome? Urol Res. 2012;40(2):95–112. doi: 10.1007/s00240-011-0448-9
- Khan SR. Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations. J Urol. 2013;189(3):803–811. doi: 10.1016/j.juro.2012.05.078
- Khan SR, Pearle MS, Robertson WG, et al. Kidney stones. Nat Rev Dis Primers. 2016;2:16008. doi: 10.1038/nrdp.2016.8
- Khan SR. Histological aspects of the “fixed-particle” model of stone formation: animal studies. Urolithiasis. 2017;45(1):75–87. doi: 10.1007/s00240-016-0949-7
- Khan SR, Canales BK. Proposal for pathogenesis-based treatment options to reduce calcium oxalate stone recurrence. Asian J Urol. 2023;10(3):246–257. doi: 10.1016/j.ajur.2023.01.008
- Khandrika L, Koul S, Meacham RB, Koul HK. Kidney injury molecule-1 is up-regulated in renal epithelial cells in response to oxalate in vitro and in renal tissues in response to hyperoxaluria in vivo. PLoS One. 2012;7(9): e44174. doi: 10.1371/journal.pone.0044174. Retraction in: PLoS One. 2020;15(6): e0234862
- Liang L, Li L, Tian J, et al. Androgen receptor enhances kidney stone-CaOx crystal formation via modulation of oxalate biosynthesis & oxidative stress. Mol Endocrinol. 2014;28(8):1291–1303. doi: 10.1210/me.2014-1047
- Liu Y, Jin X, Tian L et al. Lactiplantibacillus plantarum reduced renal calcium oxalate stones by regulating arginine metabolism in gut microbiota. Front Microbiol. 2021;12:743097. doi: 10.3389/fmicb.2021.743097
- Matsuura K, Maehara N, Hirota A, et al. Two independent modes of kidney stone suppression achieved by AIM/CD5L and KIM-1. Commun Biol. 2022;5(1):783. doi: 10.1038/s42003-022-03750-w
- Mehta M, Goldfarb DS, Nazzal L. The role of the microbiome in kidney stone formation. Int J Surg. 2016;36(Pt D):607–612. doi: 10.1016/j.ijsu.2016.11.024
- Messa P, Castellano G, Vettoretti S, et al. Vitamin D and calcium supplementation and urolithiasis: a controversial and multifaceted relationship. Nutrients. 2023;15(7):1724. doi: 10.3390/nu15071724
- Nikolic-Paterson DJ, Wang S, Lan HY. Macrophages promote renal fibrosis through direct and indirect mechanisms. Kidney Int Suppl (2011). 2014;4(1):34–38. doi: 10.1038/kisup.2014.7
- O’Kell AL, Grant DC, Khan SR. Pathogenesis of calcium oxalate urinary stone disease: species comparison of humans, dogs, and cats. Urolithiasis. 2017;45(4):329–336. doi: 10.1007/s00240-017-0978-x
- Olvera-Posada D, Dayarathna T, Dion M, et al. Kim-1 is a potential urinary biomarker of obstruction: results from a prospective cohort study. J Endourol. 2017;31(2):111–118. doi: 10.1089/end.2016.0215
- Patel M, Yarlagadda V, Adedoyin O, et al. Oxalate induces mitochondrial dysfunction and disrupts redox homeostasis in a human monocyte derived cell line. Redox Biol. 2018;15:207–215. doi: 10.1016/j.redox.2017.12.003
- Peerapen P, Thongboonkerd V. Protective cellular mechanism of estrogen against kidney stone formation: a proteomics approach and functional validation. Proteomics. 2019;19(19):e1900095. doi: 10.1002/pmic.201900095
- Peerapen P, Thongboonkerd V. Protein network analysis and functional enrichment via computational biotechnology unravel molecular and pathogenic mechanisms of kidney stone disease. Biomed J. 2023;46(2):100577. doi: 10.1016/j.bj.2023.01.001
- Peng Y, Fang Z, Liu M, et al. Testosterone induces renal tubular epithelial cell death through the HIF-1α/BNIP3 pathway. J Transl Med. 2019;17(1):62. doi: 10.1186/s12967-019-1821-7 Erratum in: J Transl Med. 2021;19(1):146.
- Peng Y, Fang Z, Liu M, et al. Correction to: Testosterone induces renal tubular epithelial cell death through the HIF-1α/BNIP3 pathway. J Transl Med. 2021;19(1):146. doi: 10.1186/s12967-021-02799-1 Erratum in: J Transl Med. 2019;17(1):62.
- Randall A. The origin and growth of renal calculi. Ann Surg. 1937;105(6):1009–1027. doi: 10.1097/00000658-193706000-00014
- Rivera M, Jaeger C, Yelfimov D, Krambeck AE. Risk of chronic kidney disease in brushite stone formers compared with idiopathic calcium oxalate stone formers. Urology. 2017;99:23–26. doi: 10.1016/j.urology.2016.08.041
- Sakhaee K. Recent advances in the pathophysiology of nephrolithiasis. Kidney Int. 2009;75(6):585–595. doi: 10.1038/ki.2008.626
- Shimshilashvili L, Aharon S, Moe OW, Ohana E. Novel human polymorphisms define a key role for the SLC26A6-stas domain in protection from Ca2+-oxalate lithogenesis. Front Pharmacol. 2020;11:405. doi: 10.3389/fphar.2020.00405
- Sinha SK, Mellody M, Carpio MB, et al. Osteopontin as a biomarker in chronic kidney disease. Biomedicines. 2023;11(5):1356. doi: 10.3390/biomedicines11051356
- Siener R, Bangen U, Sidhu H, et al. The role of Oxalobacter formigenes colonization in calcium oxalate stone disease. Kidney Int. 2013;83(6):1144–1149. doi: 10.1038/ki.2013.104
- Spatola L, Ferraro PM, Gambaro G, et al. Metabolic syndrome and uric acid nephrolithiasis: insulin resistance in focus. Metabolism. 2018;83:225–233. doi: 10.1016/j.metabol.2018.02.008
- Sueksakit K, Thongboonkerd V. Protective effects of finasteride against testosterone-induced calcium oxalate crystallization and crystal-cell adhesion. J Biol Inorg Chem. 2019;24(7):973–983. doi: 10.1007/s00775-019-01692-z
- Thielemans R, Speeckaert R, Delrue C, et al. Unveiling the hidden power of uromodulin: a promising potential biomarker for kidney diseases. Diagnostics (Basel). 2023;13(19):3077. doi: 10.3390/diagnostics13193077
- Tian L, Liu Y, Xu X, et al. Lactiplantibacillus plantarum J-15 reduced calcium oxalate kidney stones by regulating intestinal microbiota, metabolism, and inflammation in rats. FASEB J. 2022;36(6): e22340. doi: 10.1096/fj.202101972RR
- Veena CK, Josephine A, Preetha SP, et al. Mitochondrial dysfunction in an animal model of hyperoxaluria: a prophylactic approach with fucoidan. Eur J Pharmacol. 2008;579(1–3):330–336. doi: 10.1016/j.ejphar.2007.09.044
- Wang J, Wang W, Wang H, Tuo B. Physiological and pathological functions of SLC26A6. Front Med (Lausanne). 2021;7:618256. doi: 10.3389/fmed.2020.618256
- Wang Z, Zhang Y, Zhang J, et al. Recent advances on the mechanisms of kidney stone formation (Review). Int J Mol Med. 2021;48(2):149. doi: 10.3892/ijmm.2021.4982
- Wei Z, Cui Y, Tian L, et al. Probiotic Lactiplantibacillus plantarum N-1 could prevent ethylene glycol-induced kidney stones by regulating gut microbiota and enhancing intestinal barrier function. FASEB J. 2021;35(11): e21937. doi: 10.1096/fj.202100887RR
- Williams JC Jr, Worcester E, Lingeman JE. What can the microstructure of stones tell us? Urolithiasis. 2017;45(1):19–25. doi: 10.1007/s00240-016-0944-z
- Wong YV, Cook P, Somani BK. The association of metabolic syndrome and urolithiasis. Int J Endocrinol. 2015;2015:570674. doi: 10.1155/2015/570674
- Woodard LE, Welch RC, Veach RA, et al. Metabolic consequences of cystinuria. BMC Nephrol. 2019;20(1):227. doi: 10.1186/s12882-019-1417-8
- Wu XR. Interstitial calcinosis in renal papillae of genetically engineered mouse models: relation to Randall’s plaques. Urolithiasis. 2015;43 Suppl. 1(01):65–76. doi: 10.1007/s00240-014-0699-3
- Xiaoran Li X, Chen S, Feng D, et al. Calcium-sensing receptor promotes calcium oxalate crystal adhesion and renal injury in Wistar rats by promoting ROS production and subsequent regulation of PS ectropion, OPN, KIM-1, and ERK expression. Ren Fail. 2021;43(1):465–476. doi: 10.1080/0886022X.2021.1881554
- Xu Z, Yao X, Duan C, et al. Metabolic changes in kidney stone disease. Front Immunol. 2023;14:1142207. doi: 10.3389/fimmu.2023.1142207
- Yagisawa T, Ito F, Osaka Y, et al. The influence of sex hormones on renal osteopontin expression and urinary constituents in experimental urolithiasis. J Urol. 2001;166(3):1078–1082.
- Ye Z, Zeng G, Yang H, et al. The status and characteristics of urinary stone composition in China. BJU Int. 2020;125(6):801–809. doi: 10.1111/bju.14765
- Yoodee S, Thongboonkerd V. Bioinformatics and computational analyses of kidney stone modulatory proteins lead to solid experimental evidence and therapeutic potential. Biomed Pharmacother. 2023;159:114217. doi: 10.1016/j.biopha.2023.114217
- Yuan P, Sun X, Liu X, et al. Kaempferol alleviates calcium oxalate crystal-induced renal injury and crystal deposition via regulation of the AR/NOX2 signaling pathway. Phytomedicine. 2021;86:153555. doi: 10.1016/j.phymed.2021.153555
- Zee T, Bose N, Zee J, et al. α-Lipoic acid treatment prevents cystine urolithiasis in a mouse model of cystinuria. Nat Med. 2017;23(3):288–290. doi: 10.1038/nm.4280
- Zeng G, Mai Z, Xia S, et al. Prevalence of kidney stones in China: an ultrasonography based cross-sectional study. BJU Int. 2017;120(1):109–116. doi: 10.1111/bju.13828
- Zhao C, Yang H, Zhu X, et al. Oxalate-degrading enzyme recombined lactic acid bacteria strains reduce hyperoxaluria. Urology. 2018;113:253.e1–253.e7. doi: 10.1016/j.urology.2017.11.038
- Zhu W, Zhao Z, Chou FJ, et al. The protective roles of estrogen receptor β in renal calcium oxalate crystal formation via reducing the liver oxalate biosynthesis and renal oxidative stress-mediated cell injury. Oxid Med Cell Longev. 2019;2019:5305014. doi: 10.1155/2019/5305014